HEC ChangJiang Pharmaceutical

Explore the latest insights on HEC ChangJiang Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of HEC ChangJiang Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Fineline Info & Tech (Flcube.com) provides you with comprehensive information about HEC ChangJiang Pharmaceutical, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about HEC ChangJiang Pharmaceutical please access Flcube.com

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Company

YiChang HEC Reports Strong Recovery in 2022 Interim Results

CompanyDrug

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Show More